Disproportionality analysis of buprenorphine transdermal system and cardiac arrhythmia using FDA and WHO postmarketing reporting system data

RT @earth_to_jen: Disproportionality analysis of bupe transdermal system Butrans and cardiac arrhythmia using FDA and WHO postmarketing rep…

Disproportionality analysis of bupe transdermal system Butrans and cardiac arrhythmia using FDA and WHO postmarketing reporting system data @dreamr9876 @cmoraff @drrickbarnett @CarePractice

https://t.co/CuOJsFcFtV signal identified in transdermal bupe thorough QTc study, which led to dose limitation in US label, does not translate into signal of increased risk for cardiac arrhythmia in real world use assessed by method of analyzing post-marke